225 results on '"Cuccia, Liana"'
Search Results
2. Pancreatic fatty replacement as risk marker for altered glucose metabolism and cardiac iron and complications in thalassemia major
3. Left ventricular global function index is associated with myocardial iron overload and heart failure in thalassemia major patients
4. Prognostic value of multiparametric cardiac magnetic resonance in sickle cell patients
5. The impact of HCV chronic positivity and clearance on extrahepatic morbidity in thalassemia major patients: an observational study from MIOT Network
6. Quantitative T2* MRI for bone marrow iron overload: normal reference values and assessment in thalassemia major patients
7. Bone status and HCV infection in thalassemia major patients
8. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial
9. Sferocitosi: una famiglia... tre malattie
10. Cardiac involvement by CMR in different genotypic groups of thalassemia major patients
11. Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy
12. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
13. Myocardial tissue characterization by segmental T2 mapping in thalassaemia major: detecting inflammation beyond iron
14. Left Ventricle Detection from Cardiac Magnetic Resonance Relaxometry Images Using Visual Transformer
15. Multi-Parametric Cardiac Magnetic Resonance for Prediction of Heart Failure Death in Thalassemia Major
16. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?
17. Myocardial tissue characterization by segmental T2 mapping in thalassaemia major: detecting inflammation beyond iron.
18. Prognostic value of multiparametric cardiac magnetic resonance in sickle cell patients
19. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective
20. Left ventricular global function index is associated with myocardial iron overload and heart failure in thalassemia major patients
21. Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach
22. Gender differences in the development of cardiac complications: a multicentre study in a large cohort of thalassaemia major patients to optimize the timing of cardiac follow‐up
23. Gender Differences in Knowledge and Perception of Cardiovascular Disease among Italian Thalassemia Major Patients
24. Deep Learning Staging of Liver Iron Content From Multiecho MR Images
25. Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major
26. Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death
27. The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major‐intermedia dichotomy?
28. Deep Learning Staging of Liver Iron Content From Multiecho MR Images.
29. Link between Genotype and Multi-Organ Iron and Complications in Children with Transfusion-Dependent Thalassemia
30. National networking in rare diseases and reduction of cardiac burden in thalassemia major
31. The Link of Pancreatic Iron with Glucose Metabolism and Cardiac Iron in Thalassemia Intermedia: A Large, Multicenter Observational Study
32. Extramedullary hematopoiesis is associated with lower cardiac iron loading in chronically transfused thalassemia patients
33. Uncertain crisis time affects psychosocial dimensions in beta-thalassemia patients during Covid-19 pandemic: A cross-sectional study
34. Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies
35. Uncertain crisis time affects psychosocial dimensions in beta-thalassemia patients during Covid-19 pandemic: A cross-sectional study.
36. sj-docx-1-hpq-10.1177_13591053211049942 – Supplemental material for Uncertain crisis time affects psychosocial dimensions in beta-thalassemia patients during Covid-19 pandemic: A cross-sectional study
37. Long-Term Chelation Therapy with Deferasirox: Effects on Cardiac Iron Overload Measured by T2* MRI
38. National networking in rare diseases and reduction of cardiac burden in thalassemia major.
39. Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study
40. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients
41. Reliability of EMA Binding Test in the Diagnosis of Hereditary Spherocytosis in Italian Patients
42. The Close Link of Pancreatic Iron With Glucose Metabolism and With Cardiac Complications in Thalassemia Major: A Large, Multicenter Observational Study
43. Biventricular Reference Values by Body Surface Area, Age, and Gender in a Large Cohort of Well‐Treated Thalassemia Major Patients Without Heart Damage Using a Multiparametric CMR Approach
44. Long-term sequential deferiprone–deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial
45. Long‐term sequential deferiprone and deferasirox therapy in transfusion‐dependent thalassaemia patients: a prospective clinical trial
46. Genotypic groups as risk factors for cardiac magnetic resonance abnormalities and complications in thalassemia major: a large, multicentre study.
47. Biventricular Reference Values by Body Surface Area, Age, and Gender in a Large Cohort of Well-Treated Thalassemia Major Patients Without Heart Damage Using a Multiparametric CMR Approach.
48. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine
49. Is the Time of Revisiting Classification of Thalassemia Syndromes According with the Phenotype Severity?
50. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.